Another KRASG12C Inhibitor in Ph. III, Bayer’s Massive FXIa Ph. III Clinical Trial, and 21 Other Molecules in the News

In this update of small molecules in the news for February 2023, we will cover recent:

Molecules in Motion: clinical trial updates and FDA filings
Negative Readouts: halted, discontinued or altered clinical trials 
Million-Dollar Molecules: recent M&A’s, IPOs, and other fundraising
Potential Approvals: recent NDA filings and upcoming PDUFA dates
Where Are They Now? updates on past Molecules of the Month

Want updates like this straight to your inbox? Sign up for our weekly newsletter here.

Molecules in Motion 


RG6330 (GDC-6036, divarasib) oral KRASG12C inhibitor entered Ph. III trials for NSCLC

Roche has added RG6330 to the Ph. III B-FAST study investigating multiple therapies as single agents or in combination for non-small cell lung cancer (NSCLC, NCT03178552), adding another late-stage contender to this competitive field. The new arm will compare RG6330 monotherapy (QD) against docetaxel in second-line KRASG12C-mutant disease. Like approved covalent molecules sotorasib and adagrasib, the compound shuts down oncogenic signaling by locking KRASG12C into the inactive GDP-bound state. KRASG12C is a hotly pursued target that we have covered in depth previously, including articles on sotorasib (Lumakras, Amgen),  MRTX849 (Krazati, Mirati), Revolution Medicines’ RM-018, AstraZeneca’s compound 25, Novartis’s JDQ443, and Boehringer Ingelheim’s BI-0474, among others. This recent article discusses how new inhibitors could differentiate.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!